Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David M Simpson, MD
Icahn School of Medicine at Mount Sinai
Principal Investigator - Jeffrey Tobias, MD
NeurogesX
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
35 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Neurogesx Investigational Site
Phoenix, Arizona, United States
- Neurogesx Investigational Site
Phoenix, Arizona, United States
- Neurogesx Investigational Site
Berkeley, California, United States
- Neurogesx Investigational Site
San Diego, California, United States
- Neurogesx Investigational Site
San Francisco, California, United States
- Neurogesx Investigational Site
Stanford, California, United States
- Neurogesx Investigational Site
West Hollywood, California, United States
- Neurogesx Investigational Site
Fort Lauderdale, Florida, United States
- Neurogesx Investigational Site
Miami, Florida, United States
- Neurogesx Investigational Site
Miami, Florida, United States
- Neurogesx Investigational Site
North Palm Beach, Florida, United States
- Neurogesx Investigational Site
Orlando, Florida, United States
- Neurogesx Investigational Site
Sunrise, Florida, United States
- Neurogesx Investigational Site
Vero Beach, Florida, United States
- Neurogesx Investigational Site
Honolulu, Hawaii, United States
- Neurogesx Investigational Site
Chicago, Illinois, United States
- Neurogesx Investigational Site
Lexington, Kentucky, United States
- Neurogesx Investigational Site
Baltimore, Maryland, United States
- Neurogesx Investigational Site
Boston, Massachusetts, United States
- Neurogesx Investigational Site
Springfield, Massachusetts, United States
- Neurogesx Investigational Site
Detroit, Michigan, United States
- Neurogesx Investigational Site
Minneapolis, Minnesota, United States
- Neurogesx Investigational Site
St Louis, Missouri, United States
- Neurogesx Investigational Site
Camden, New Jersey, United States
- Neurogesx Investigational Site
Albany, New York, United States
- Neurogesx Investigational Site
New York, New York, United States
- Neurogesx Investigational Site
New York, New York, United States
- Neurogesx Investigational Site
Chapel Hill, North Carolina, United States
- Neurogesx Investigational Site
Cleveland, Ohio, United States
- Neurogesx Investigational Site
Portland, Oregon, United States
- Neurogesx Investigational Site
Austin, Texas, United States
- Neurogesx Investigational Site
Dallas, Texas, United States
- Neurogesx Investigational Site
Houston, Texas, United States
- Neurogesx Investigational Site
San Antonio, Texas, United States
- Neurogesx Investigational Site
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2003
- Primary completion
- —
- Completion
- 30 Nov 2005
- Last update posted
- 6 Mar 2008
- Registered enrollment
- 300
- Registry id
- NCT00064623
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.